Journal ArticleDOI
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Björn Dahlöf,Richard B. Devereux,Sverre E. Kjeldsen,Stevo Julius,Gareth Beevers,Ulf de Faire,Frej Fyhrquist,Hans Ibsen,Krister Kristiansson,Ole Lederballe-Pedersen,Lars H Lindholm,Markku S. Nieminen,Per Omvik,Suzanne Oparil,Hans Wedel +14 more
TLDR
Losartan prevents more cardiovascular morbidity and death than atenolol for a similar reduction in blood pressure and is better tolerated, while new-onset diabetes was less frequent with losartan.About:
This article is published in The Lancet.The article was published on 2002-03-23. It has received 5380 citations till now. The article focuses on the topics: Angiotensin II & Atenolol.read more
Citations
More filters
Journal ArticleDOI
Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs - overview and meta-analyses.
TL;DR: The results of all available evidence from head-to-head drug class comparisons do not allow the formulation of a fixed paradigm of drug choice valuable for all hypertensive patients, but the differences found may suggest specific choices in specific conditions, or preferable combinations of drugs.
Journal ArticleDOI
RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection
Christian Werner,Magnus Baumhäkel,Koon K. Teo,Roland E. Schmieder,Johannes F.E. Mann,Thomas Unger,Salim Yusuf,Michael Böhm +7 more
TL;DR: While combined RAS-inhibition is not generally indicated in patients along the cardio-reno-vascular continuum, it has already proven to be effective in heart failure patients with incomplete neuroendocrine blockade and in secondary prevention, monotherapy with either RAS inhibitor is equally efficacious.
Journal ArticleDOI
QRS Duration and QT Interval Predict Mortality in Hypertensive Patients With Left Ventricular Hypertrophy: The Losartan Intervention for Endpoint Reduction in Hypertension Study
Lasse Oikarinen,Markku S. Nieminen,Matti Viitasalo,Lauri Toivonen,Sverker Jern,Björn Dahlöf,Richard B. Devereux,Peter M. Okin +7 more
TL;DR: In a hypertensive risk population identified by electrocardiographic left ventricular hypertrophy, increased QRS duration and maximum rate-adjusted QTapex interval can further stratify mortality risk even in the setting of effective blood pressure-lowering treatment.
Journal ArticleDOI
Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide
TL;DR: Olmesartan medoxomil plus HCTZ produced greater reductions in both SeDBP and seated systolic blood pressure (SeSBP) at week 8 than did monotherapy with either component.
Journal ArticleDOI
Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
Gianpaolo Reboldi,Fabio Angeli,Claudio Cavallini,Giorgio Gentile,Giuseppe Mancia,Paolo Verdecchia +5 more
TL;DR: It is suggested that angiotensin II receptor blockers are as effective as angiotENSin-converting enzyme inhibitors on the risk of myocardial infarction, cardiovascular mortality and total mortality.
References
More filters
Journal ArticleDOI
Effects of an angiotensin-converting -enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
TL;DR: Ramipril significantly reduces the rates of death, myocardial infarction, and stroke in a broad range of high-risk patients who are not known to have a low ejection fraction or heart failure.
Journal ArticleDOI
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
Barry M. Brenner,Mark E. Cooper,Dick de Zeeuw,William F. Keane,William E. Mitch,Hans-Henrik Parving,Giuseppe Remuzzi,Steven M. Snapinn,Zhonxin Zhang,Shahnaz Shahinfar +9 more
TL;DR: Losartan conferred significant renal benefits in patients with type 2 diabetes and nephropathy, and it was generally well tolerated.
Journal ArticleDOI
Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial
Lennart Hansson,Lars H Lindholm,Leo Niskanen,Jan Lanke,Thomas Hedner,Anders Niklason,Kimmo Luomanmäki,Björn Dahlöf,Ulf de Faire,Claes Mörlin,Bengt E. Karlberg,P. O. Wester,Jan-Erik Björck +12 more
TL;DR: Captopril and conventional treatment did not differ in efficacy in preventing cardiovascular morbidity and mortality and the difference in stroke risk was probably due to the lower levels of blood pressure obtained initially in previously treated patients randomised to conventional therapy.
Journal ArticleDOI
An updated coronary risk profile. A statement for health professionals.
TL;DR: Using a simple worksheet, a patient's 5- and 10-year CHD risks can be estimated using components of the profile selected because they are objective and strongly and independently related to CHD.
Journal ArticleDOI
Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration
TL;DR: Strong evidence of benefits of ACE inhibitors and calcium antagonists is provided by the overviews of placebo-controlled trials, and data from continuing trials of blood-pressure-lowering drugs will substantially increase the evidence available about any real differences that might exist between regimens.
Related Papers (5)
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
Curt D. Furberg,Jackson T. Wright,Barry R. Davis,Jeffrey A. Cutler,Michael H. Alderman,Henry R. Black,William C. Cushman,Richard H. Grimm,L. Julian Haywood,Frans H. H. Leenen,Suzanne Oparil,Jeffrey L. Probstfield,Paul K. Whelton,Chuke Nwachuku,David Gordon,Michael A. Proschan,Paula Einhom,Charles E. Ford,Linda B. Piller,I. Kay Dunn,David C. Goff,Sara L. Pressel,Judy Bettencourt,Barbara DeLeon,Lara M. Simpson,Joe Blanton,Therese S. Geraci,Sandra M. Walsh,Christine Nelson,Mahboob Rahman,Anne Juratovac,Robert Pospisil,Lillian Carroll,Sheila Sullivan,Jeanne Russo,Gail Barone,Rudy Christian,Sharon Feldman,Tracy Lucente,David A. Calhoun,Kim Jenkins,Peggy McDowell,Janice Johnson,Connie Kingry,Juan Alzate,Karen L. Margolis,Leslie Ann Holland-Klemme,Brenda Jaeger,Jeff D. Williamson,Gail T. Louis,Pamela Ragusa,Angela Williard,R. L Sue Ferguson,Joanna Tanner,John H. Eckfeldt,Richard S. Crow,John Pelosi +56 more